Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients.
OBJECTIVE
To compare genotypic and phenotypic HIV-1 drug resistance assays.


METHODS
Protease inhibitor (PI) susceptibility was phenotypically analysed in HIV-1 isolates and recombinant viruses expressing proteases from viral isolates. Two genotypic interpretation methods were carried out in parallel.


RESULTS
Entirely concordant resistance levels were shown in 5/10 (50%) highly active anti-retroviral therapy (HAART)-experienced patients, whereas minor discrepancies were observed in the remaining five patients.


CONCLUSIONS
The four assays provide comparable results. The recombinant virus phenotypic assay may provide the most accurate evaluation of resistance; however, genotypic interpretation procedures are helpful for daily therapeutic decisions.
Paolucci
Stefania
S
Servizio di Virologia, IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
Baldanti
Fausto
F
Zavattoni
Maurizio
M
Comolli
Giuditta
G
Labò
Nazzarena
N
Menzo
Stefano
S
Clementi
Massimo
M
Gerna
Giuseppe
G
D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data; D024882:Drug Resistance, Viral / Q000235:genetics*; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics* / Q000302:isolation & purification; D006367:HeLa Cells; D006801:Humans; D010641:Phenotype; D011995:Recombination, Genetic
D017320:HIV Protease Inhibitors